Conditions: Atrophy Vaginal Diseases
Keywords: Menopausal symptoms Vulvar and vaginal atrophy in menopausal women Vaginal atrophy Urogenital atrophy
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 301
Healthy volunteers: no

Brief summary:
The objective of the study was to assess the long-term safety of daily doses of ospemifene 60 mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a uterus.

Detailed description:

Arms:
arm 1: Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.

Interventions: intervention 1: Ospemifene 60Mg Oral Tablet
Intervention descriptions: intervention 1: None

Protocol document: